Novel RNA-Seq Signatures Post-Methamphetamine and Oxycodone Use in a Model of HIV-Associated Neurocognitive Disorders

In the 21st century, the effects of HIV-associated neurocognitive disorders (HAND) have been significantly reduced in individuals due to the development of antiretroviral therapies (ARTs). However, the growing epidemic of polysubstance use (PSU) has led to concern for the effects of PSU on HIV-seropositive individuals. To effectively treat individuals affected by HAND, it is critical to understand the biological mechanisms affected by PSU, including the identification of novel markers. To fill this important knowledge gap, we used an in vivo HIV-1 Transgenic (HIV-1 Tg) animal model to investigate the effects of the combined use of chronic methamphetamine (METH) and oxycodone (oxy). A RNA-Seq analysis on the striatum—a brain region that is primarily targeted by both HIV and drugs of abuse—identified key differentially expressed markers post-METH and oxy exposure. Furthermore, ClueGO analysis and Ingenuity Pathway Analysis (IPA) revealed crucial molecular and biological functions associated with ATP-activated adenosine receptors, neuropeptide hormone activity, and the oxytocin signaling pathway to be altered between the different treatment groups. The current study further reveals the harmful effects of chronic PSU and HIV infection that can subsequently impact neurological outcomes in polysubstance users with HAND.

[1]  A. Kaye,et al.  Oxytocin, a Novel Treatment for Methamphetamine Use Disorder , 2022, Neurology international.

[2]  K. Leong,et al.  Oxytocin and Addiction: Potential Glutamatergic Mechanisms , 2021, International journal of molecular sciences.

[3]  W. Compton,et al.  Polysubstance use in the U.S. opioid crisis , 2020, Molecular Psychiatry.

[4]  N. Davis,et al.  Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants — 24 States and the District of Columbia, January–June 2019 , 2020, MMWR. Morbidity and mortality weekly report.

[5]  Y. Israel,et al.  Oxidative Stress and Neuroinflammation as a Pivot in Drug Abuse. A Focus on the Therapeutic Potential of Antioxidant and Anti-Inflammatory Agents and Biomolecules , 2020, Antioxidants.

[6]  S. Ferguson,et al.  One Is Not Enough: Understanding and Modeling Polysubstance Use , 2020, Frontiers in Neuroscience.

[7]  Kalaiselvi Sivalingam,et al.  Effects of Drugs of Abuse on the Blood-Brain Barrier: A Brief Overview , 2020, Frontiers in Neuroscience.

[8]  H. Becker,et al.  The role of oxytocin in alcohol and drug abuse , 2020, Brain Research.

[9]  T. Cicero,et al.  Polysubstance Use: A Broader Understanding of Substance Use During the Opioid Crisis. , 2019, American journal of public health.

[10]  B. Maher,et al.  Substance Use Disorder, Intravenous Injection, and HIV Infection: A Review , 2019, Cell transplantation.

[11]  M. Rao,et al.  Chronic oxycodone induces axonal degeneration in rat brain , 2018, BMC neuroscience.

[12]  S. Aquaro,et al.  The Role of HIV Infection in Neurologic Injury , 2017, Brain sciences.

[13]  C. Sommer,et al.  Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study , 2016, Schizophrenia Research.

[14]  D. Slattery,et al.  Oxytocin in General Anxiety and Social Fear: A Translational Approach , 2016, Biological Psychiatry.

[15]  R. See,et al.  Oxytocin decreases cocaine taking, cocaine seeking, and locomotor activity in female rats. , 2016, Experimental and clinical psychopharmacology.

[16]  Xiu-Ti Hu HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions. , 2015, Current drug targets.

[17]  C. Pantelis,et al.  Effects of oxytocin and genetic variants on brain and behaviour: Implications for treatment in schizophrenia , 2015, Schizophrenia Research.

[18]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[19]  Ming D. Li,et al.  Acquisition and long-term retention of spatial learning in the human immunodeficiency virus-1 transgenic rat: effects of repeated nicotine treatment , 2013, Journal of NeuroVirology.

[20]  M. Berridge Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia , 2013, Prion.

[21]  Peter Kirsch,et al.  Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine , 2011, Nature Reviews Neuroscience.

[22]  G. Koob,et al.  Role of Corticotropin-Releasing Factor in Drug Addiction , 2011, CNS drugs.

[23]  Linda Chang,et al.  Methamphetamine-Induced Behavioral and Physiological Effects in Adolescent and Adult HIV-1 Transgenic Rats , 2010, Journal of Neuroimmune Pharmacology.

[24]  M. Vigorito,et al.  Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat , 2009, Journal of NeuroVirology.

[25]  W. Young,et al.  Oxytocin: The great facilitator of life , 2009, Progress in Neurobiology.

[26]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[27]  W. Young,et al.  Vasopressin: Behavioral roles of an “original” neuropeptide , 2008, Progress in Neurobiology.

[28]  A. Baskin-Sommers,et al.  The co-occurrence of substance use and high-risk behaviors. , 2006, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[29]  W. Gan,et al.  ATP mediates rapid microglial response to local brain injury in vivo , 2005, Nature Neuroscience.

[30]  M. Reitz,et al.  An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Y. Imai,et al.  Extracellular ATP or ADP Induce Chemotaxis of Cultured Microglia through Gi/o-Coupled P2Y Receptors , 2001, The Journal of Neuroscience.

[32]  David Z. Chen,et al.  METHOD Open Access , 2014 .